News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
730,243 Results
Type
Article (41337)
Company Profile (265)
Press Release (688624)
Multimedia
Podcasts (91)
Webinars (20)
Section
Business (204837)
Career Advice (2035)
Deals (35579)
Drug Delivery (128)
Drug Development (81507)
Employer Resources (174)
FDA (16503)
Job Trends (14980)
News (346800)
Policy (32750)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2593)
Accelerated approval (46)
Adcomms (26)
Allergies (170)
Alliances (49580)
ALS (210)
Alzheimer's disease (1782)
Antibody-drug conjugate (ADC) (440)
Approvals (16876)
Artificial intelligence (653)
Autoimmune disease (281)
Automation (54)
Bankruptcy (362)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (219)
Biotechnology (175)
Bladder cancer (186)
Brain cancer (70)
Breast cancer (743)
Cancer (5756)
Cardiovascular disease (466)
Career advice (1726)
Career pathing (42)
CAR-T (328)
CDC (56)
Celiac Disease (3)
Cell therapy (885)
Cervical cancer (47)
Clinical research (70736)
Collaboration (2033)
Company closure (5)
Compensation (1383)
Complete response letters (78)
COVID-19 (2740)
CRISPR (107)
C-suite (1106)
Cystic fibrosis (151)
Data (7767)
Decentralized trials (3)
Denatured (27)
Depression (159)
Dermatology (83)
Diabetes (584)
Diagnostics (6916)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (314)
Drug pricing (200)
Drug shortages (31)
Duchenne muscular dystrophy (280)
Earnings (91940)
Editorial (66)
Employer branding (21)
Employer resources (153)
Events (119364)
Executive appointments (1075)
FDA (20192)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (16)
Frontotemporal dementia (34)
Funding (1704)
Gene editing (232)
Generative AI (55)
Gene therapy (712)
GLP-1 (1049)
Government (4728)
Grass and pollen (6)
Guidances (408)
Healthcare (18988)
HIV (79)
Huntington's disease (56)
IgA nephropathy (96)
Immunology and inflammation (285)
Immuno-oncology (91)
Indications (189)
Infectious disease (3077)
Inflammatory bowel disease (216)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (288)
Interviews (320)
IPO (16666)
IRA (50)
Job creations (3647)
Job search strategy (1432)
JPM (58)
Kidney cancer (19)
Labor market (98)
Layoffs (562)
Leadership (39)
Legal (7953)
Liver cancer (99)
Longevity (32)
Lung cancer (757)
Lymphoma (428)
Machine learning (59)
Management (59)
Manufacturing (1029)
MASH (183)
Medical device (13918)
Medtech (14036)
Mergers & acquisitions (20152)
Metabolic disorders (1486)
mRNA (203)
Multiple sclerosis (187)
NASH (17)
Neurodegenerative disease (411)
Neuropsychiatric disorders (105)
Neuroscience (3278)
Neurotech (1)
NextGen: Class of 2026 (6521)
Non-profit (4530)
Now hiring (77)
Obesity (696)
Opinion (286)
Ovarian cancer (218)
Pain (250)
Pancreatic cancer (294)
Parkinson's disease (356)
Partnered (33)
Patents (592)
Patient recruitment (665)
Peanut (62)
People (59541)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (22048)
Phase 2 (31162)
Phase 3 (23191)
Pipeline (8493)
Policy (313)
Postmarket research (2568)
Preclinical (9393)
Press Release (64)
Prostate cancer (293)
Psychedelics (54)
Radiopharmaceuticals (319)
Rare diseases (1065)
Real estate (5968)
Recruiting (71)
Regulatory (25357)
Reports (56)
Research institute (2413)
Resumes & cover letters (353)
Rett syndrome (39)
RNA editing (21)
RSV (88)
Schizophrenia (176)
Series A (286)
Series B (211)
Service/supplier (11)
Sickle cell disease (111)
Special edition (23)
Spinal muscular atrophy (165)
Sponsored (48)
Startups (3638)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (62)
Vaccines (1088)
Venture capital (107)
Weight loss (448)
Women's health (124)
Worklife (20)
Date
Today (225)
Last 7 days (932)
Last 30 days (3476)
Last 365 days (30241)
2026 (11987)
2025 (30170)
2024 (35211)
2023 (40072)
2022 (51176)
2021 (55707)
2020 (54081)
2019 (46537)
2018 (35015)
2017 (32108)
2016 (31479)
2015 (37551)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (741)
Alabama (92)
Alaska (7)
Arizona (347)
Arkansas (14)
Asia (39648)
Australia (6500)
California (13149)
Canada (3728)
China (1326)
Colorado (564)
Connecticut (571)
Delaware (401)
Europe (85787)
Florida (1964)
Georgia (420)
Hawaii (3)
Idaho (62)
Illinois (1045)
India (88)
Indiana (597)
Iowa (23)
Japan (529)
Kansas (130)
Kentucky (50)
Louisiana (40)
Maine (75)
Maryland (1578)
Massachusetts (9376)
Michigan (359)
Minnesota (711)
Mississippi (6)
Missouri (144)
Montana (33)
Nebraska (29)
Nevada (140)
New Hampshire (84)
New Jersey (3455)
New Mexico (29)
New York (3434)
North Carolina (1665)
North Dakota (9)
Northern California (6585)
Ohio (393)
Oklahoma (23)
Oregon (41)
Pennsylvania (2641)
Puerto Rico (29)
Rhode Island (50)
South America (1112)
South Carolina (85)
South Dakota (2)
Southern California (5185)
Tennessee (209)
Texas (2084)
United States (46367)
Utah (392)
Vermont (1)
Virginia (316)
Washington D.C. (80)
Washington State (1053)
West Virginia (4)
Wisconsin (124)
Wyoming (2)
730,243 Results for "athersys inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
Athersys, Inc. Announces Pricing of $3.5 Million Public Offering
Athersys, Inc., announced the pricing of its “reasonable best efforts” public offering of 10,937,500 shares of common stock at a purchase price of $0.32 per share.
August 17, 2023
·
4 min read
Business
Athersys Reports Third Quarter 2023 Financial Results and Business Highlights
Athersys, Inc. announced financial results for the three and nine months ended September 30, 2023 and provided a business update.
November 16, 2023
·
11 min read
Business
Athersys Director Jane Wasman Appointed Board Chair
Athersys, Inc., a regenerative medicine company developing MultiStem® for critical care indications, announces changes to its Board of Directors following the Company’s recent 2023 Annual Meeting of Stockholders.
October 2, 2023
·
8 min read
BioMidwest
Athersys Restructures Debt with Supplier
Athersys, Inc., a regenerative medicine company developing MultiStem® cell therapy for critical care indications announced it has restructured its outstanding debt with a supplier.
May 23, 2023
·
8 min read
Business
Athersys Appoints Neema Mayhugh, PhD to its Board of Directors
Athersys, Inc., a regenerative medicine company developing MultiStem® for critical care indications, announced the appointment of Neema Mayhugh, PhD to its Board of Directors.
August 11, 2023
·
10 min read
Press Releases
Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace
May 13, 2026
·
3 min read
Press Releases
Exagen Inc. Reports First Quarter 2026 Results
May 11, 2026
·
10 min read
Press Releases
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
May 5, 2026
·
6 min read
BioMidwest
Athersys Licenses its Animal Health Assets to Ardent Animal Health
Athersys, Inc., a cell therapy and regenerative medicine company developing MultiStem® for critical care indications, and Multipotent Adult Progenitor Cell technology for equine, canine, and feline health applications, announces the signing of a licensing agreement with Ardent Animal Health.
October 3, 2023
·
10 min read
Press Releases
COSCIENS Biopharma Inc. Reports Q1 2026 Results
May 13, 2026
·
8 min read
1 of 73,025
Next
